Evidence map›Paper›PMID 40272146›Full record

Trial reportCancer medicine2025

Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [

Marianne Pavel, Martyn E Caplin, Philippe Ruszniewski, Marianna Hertelendi, Eric P Krenning, Jonathan R Strosberg, NETTER‐1 Study Group

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marianne PavelDepartment of Medicine 1, Uniklinikum Erlangen and Comprehensive Cancer Center CCC-EMN, Friedrich Alexander University Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0000-0002-9669-5294
Martyn E CaplinNeuroendocrine Tumour Unit, Royal Free Hospital, London, UK.
Philippe RuszniewskiUniversité Paris Cité and Department of Pancreatology and Digestive Oncology, Beaujon Hospital, Clichy, France.
Marianna HertelendiNovartis AG, Basel, Switzerland.
Eric P KrenningCyclotron Rotterdam B.V., Erasmus Medical Center, Rotterdam, the Netherlands.
Jonathan R StrosbergGI Oncology, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, Florida, USA.
NETTER‐1 Study Group

Funding

Advanced Accelerator Applications, a Novartis Company
6 · The paper itself

Abstract

backgroundIn many solid tumors, early tumor shrinkage predicts the durability of treatment response. It is unclear whether this is the case for neuroendocrine tumors treated with peptide receptor radionuclide therapy (PRRT).

methodsData from the phase III NETTER-1 study of [

resultsOverall, 117 patients were treated with

conclusionsThese results suggest the benefit of PRRT and the potential PFS and OS benefit of

Indexed as

Neuroendocrine TumorsOctreotideOrganometallic CompoundsRadiopharmaceuticalsAdultAgedDisease ProgressionFemaleHumansMaleMiddle AgedProgression-Free SurvivalTreatment Outcomelutetium Lu 177 dotatateOctreotideOrganometallic CompoundsRadiopharmaceuticals[177Lu]Lu‐DOTA‐TATEneuroendocrine tumoroverall survivalprogression‐free survivaltumor shrinkage

Identifiers

PMID40272146
PMCPMC12020026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.